Blog

Despite Headline Risks, Disclosure on Drug Pricing Remains Limited for Pharmaceuticals Companies

How and why SASB is working towards enhanced disclosure on pricing strategies. In 2016, drug pricing emerged as a headline risk for the pharmaceuticals industry. Several cases demonstrated how pricing...
Published by SASB
Read more

Moving from Provisional to Codified: An Update on the Consultation Period

SASB’s deep consultation process on the Provisional Standards and proposed updates is going “full speed ahead.” We invite corporate issuers and investors interested in participating to reach out to schedule...
Published by SASB
Read more

A Letter from Jean Rogers, SASB’s CEO

Dear SASB Stakeholders, Four years ago, SASB embarked upon an ambitious task. We promised the markets that by March 2016 we would issue sustainability accounting standards for all major industries...
Published by Jill Richardson
Read more